On two targets

Scientists have found a new target for the treatment of aggressive cancer

Svetlana Maslova, Hi-tech+

The first positive results of experimental therapy were obtained on cultures of blood cancer cells, however, the potential of treatment is not organic by oncohematological diseases. Therapy is aimed at two targets at once, which work in tandem in the body and provoke the development of a tumor.

Scientists from the USA have discovered a new function of the enzyme EZH2, which modulates chromatin. EZH2 plays an important role in the progression of cancer, but until now, drugs could not completely block the activity of the enzyme to defeat cancer. Now a new therapeutic approach has solved this problem, it is reported on the website of the Linberger Comprehensive Cancer Center in University of North Carolina.

The paper by Wang et al. EZH2 noncanonically binds cMYC and p300 through a cryptic transactivation domain to mediate gene activation and promote oncogenesis is published in the journal Nature Cell Biology – VM.

Experiments have shown that the enzymes EZH2 and cMYC can directly bind to each other, triggering gene expression programs specific to cancer cells. "This explains why modern low—molecular-weight EZH2 inhibitors could not completely block it," the authors commented.

The new experimental drug MS177 simultaneously affects EZH2 and cMYC and achieves a targeted effect in cancer cells. First of all, scientists expect that MS177 will significantly improve the results of treatment of acute leukemia, but it is promising for other types of cancer. Further research should confirm this hypothesis.

Portal "Eternal youth" http://vechnayamolodost.ru